FDA urged to require black-box warnings on ADHD drugs

02/10/2006 | Washington Post (tiered subscription model), The

An FDA advisory group assigned to discuss ways of assessing drug risks instead urged the agency to require black-box warnings on the labels of methylphenidate drugs, including Concerta, Methylin and Ritalin, and amphetamines such as Adderall. The panel voted 8 to 7 for the warnings after reviewing reports associating the attention-deficit hyperactivity disorder drugs with heart attacks and toxic reactions. Advisers said part of their decision rested on the view that the drugs are being overprescribed, noting about 10% of 10-year-old American males are taking them and the number of adult users is growing rapidly.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA